Perseus Proteomics Inc
TSE:4882

Watchlist Manager
Perseus Proteomics Inc Logo
Perseus Proteomics Inc
TSE:4882
Watchlist
Price: 723 JPY 7.59% Market Closed
Market Cap: 10.6B JPY
Have any thoughts about
Perseus Proteomics Inc?
Write Note

Perseus Proteomics Inc
Retained Earnings

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Perseus Proteomics Inc
Retained Earnings Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Retained Earnings CAGR 3Y CAGR 5Y CAGR 10Y
Perseus Proteomics Inc
TSE:4882
Retained Earnings
-ÂĄ2.8B
CAGR 3-Years
-90%
CAGR 5-Years
-40%
CAGR 10-Years
N/A
GNI Group Ltd
TSE:2160
Retained Earnings
ÂĄ10.6B
CAGR 3-Years
182%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
PeptiDream Inc
TSE:4587
Retained Earnings
ÂĄ52B
CAGR 3-Years
44%
CAGR 5-Years
39%
CAGR 10-Years
63%
Takara Bio Inc
TSE:4974
Retained Earnings
ÂĄ50.4B
CAGR 3-Years
17%
CAGR 5-Years
25%
CAGR 10-Years
21%
Pharma Foods International Co Ltd
TSE:2929
Retained Earnings
ÂĄ8.4B
CAGR 3-Years
22%
CAGR 5-Years
78%
CAGR 10-Years
N/A
C
Cuorips Inc
TSE:4894
Retained Earnings
-ÂĄ2.1B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Perseus Proteomics Inc
Glance View

Market Cap
10.3B JPY
Industry
Biotechnology

Perseus Proteomics, Inc. is a holding company that develops antibody-based therapeutics and diagnostics. The company is headquartered in Meguro-Ku, Tokyo-To and currently employs 21 full-time employees. The company went IPO on 2021-06-22. The firm is involved in the research and development of therapeutic drugs for cancer and other diseases and related businesses. The firm is involved in the research, development, licensing, and manufacturing method establishment for commercialization in the fields of drug discovery, antibody research support, as well as antibody and reagent sales. The products include PPMX-T001, a therapeutic agent that targets glypican 3 (GPC3) present on the surface of cancer cell membranes; PPMX-T002, a therapeutic agent that targets cadherin 3 (CDH3) present on the surface of cancer cells; PPMX-T003, a therapeutic agent that targets the transferrin receptor (TfR); PPMX-T004 therapeutic agent targeting cadherin 3 (CDH3) and others.

Intrinsic Value
719.16 JPY
Overvaluation 1%
Intrinsic Value
Price

See Also

What is Perseus Proteomics Inc's Retained Earnings?
Retained Earnings
-2.8B JPY

Based on the financial report for Mar 31, 2024, Perseus Proteomics Inc's Retained Earnings amounts to -2.8B JPY.

What is Perseus Proteomics Inc's Retained Earnings growth rate?
Retained Earnings CAGR 5Y
-40%

Over the last year, the Retained Earnings growth was -60%. The average annual Retained Earnings growth rates for Perseus Proteomics Inc have been -90% over the past three years , -40% over the past five years .

Back to Top